Spectrum Planning & Advisory Services’s Intellia Therapeutics NTLA Stock Holding History

Spectrum Planning & Advisory Services’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,503	Closed	-$252K	–	47
2022 Q3	$252K	Sell	4,503 -164	-4%	-$10.2K	0.25%	44
2022 Q2	$242K	Sell	4,667 -2,093	-31%	-$106K	0.25%	35
2022 Q1	$491K	Hold	6,760	–	–	0.45%	31
2021 Q4	$799K	Hold	6,760	–	–	0.73%	27
2021 Q3	$907K	Sell	6,760 -145	-2%	-$22K	0.89%	26
2021 Q2	$1.12M	Sell	6,905 -11,616	-63%	-$905K	1.07%	25
2021 Q1	$1.49M	Buy	18,521 +200	+1%	+$13.4K	1.53%	19
2020 Q4	$997K	Buy	+18,321	New	+$665K	1.07%	24

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Spectrum Planning & Advisory Services's NTLA Position: Q4 2022 in Review

Spectrum Planning & Advisory Services sold out of Intellia Therapeutics (NTLA) in Q4 2022, closing a stake of 4,503 shares — an estimated $252K sold.

Spectrum Planning & Advisory Services first reported a position in NTLA in Q4 2020 and held it in 8 quarters. The position peaked at $1.49M in Q1 2021. 303 funds tracked by Wall St. Rank hold NTLA as of Q4 2022.

Spectrum Planning & Advisory Services reported no remaining Intellia Therapeutics position as of Q4 2022 after selling out during the quarter.
Spectrum Planning & Advisory Services sold 4,503 Intellia Therapeutics shares in Q4 2022, an estimated $252K.
Spectrum Planning & Advisory Services first reported a position in Intellia Therapeutics in Q4 2020 and held it in 8 quarters.
Spectrum Planning & Advisory Services's Intellia Therapeutics position peaked at $1.49M in Q1 2021.
303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2022.

Based on Spectrum Planning & Advisory Services's 13F filing for Q4 2022, filed 20 Jan 2023.